Genmab Boosts Share Capital Through Employee Warrant Exercise
Company Announcement
On November 18, 2025, Genmab A/S (NASDAQ: GMAB) announced the increase of its share capital following the exercise of employee warrants.
This increase involves a total of 32,059 new shares, issued without preemption rights for existing shareholders or others. The shares will be subscribed at various cash prices, breaking down as follows:
10,033 shares at DKK 1,025.00,
310 shares at DKK 1,147.50,
1,478 shares at DKK 1,161.00,
5,847 shares at DKK 1,334.50,
675 shares at DKK 1,362.50, and
13,716 shares at DKK 1,615.00.
The company anticipates proceeds totaling approximately DKK 43.2 million from this capital increase, which represents about 0.05% of Genmab's total share capital.
Once registered with the Danish Business Authority, the new shares will be ordinary shares, fully transferable and without any special rights. They will confer rights to dividends and other rights associated with Genmab as of subscription.
According to section 32 of the Danish Capital Markets Act, the adjusted nominal value of Genmab A/S' share capital post-increase is recorded at DKK 64,238,408, comprised of 64,238,408 shares, each with a nominal value of DKK 1, equating to an equal number of votes.
About Genmab
Genmab is a leading international biotechnology firm dedicated to advancing innovative antibody therapeutics that aim to improve patients' lives. Established in 1999 and headquartered in Copenhagen, Denmark, Genmab has over 25 years of expertise in developing advanced antibody technology platforms. The company leverages cutting-edge quantitative and data sciences, creating a diverse pipeline of therapeutic solutions.
Genmab's portfolio includes novel therapies such as bispecific T-cell engagers, adorable antibody-drug conjugates, and next-generation immune checkpoint modulators among others. By 2030, Genmab envisions a transformative approach for individuals facing cancer and serious diseases through its groundbreaking antibody medicines.
The company operates globally, extending its innovative reach across North America, Europe, and the Asia Pacific region. For additional insights, their official site operates as a comprehensive resource.
Contact Information
For further inquiries, please contact:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
Frequently Asked Questions
What prompted the increase in Genmab's share capital?
The capital increase resulted from the exercise of employee warrants.
How many new shares are being issued by Genmab?
A total of 32,059 new shares are being issued.
What will the proceeds from the share capital increase be used for?
The proceeds, approximately DKK 43.2 million, will support Genmab's ongoing research and development initiatives.
When will the new shares be listed?
The new shares are expected to be listed on Nasdaq Copenhagen following their registration with the Danish Business Authority.
What is Genmab's vision for the future?
Genmab aims to transform the lives of patients through innovative antibody medicines by the year 2030.
